The CEO's $6.8M open-market sale at $69.33 is the largest single insider sale in the cluster and represents a meaningful reduction in his stake. While insider sales are generally weak signals, the concentration in C-suite and the cluster's timing after a period of strong analyst bullishness (89% buy) warrants caution. Monitor for any upcoming negative catalyst (data readout, regulatory update) that may have prompted the selling. The historical T+20 drift on CYTK reports has been consistently negative (-6.12% avg), suggesting the stock may face near-term headwinds.
Price Chart
Executive Summary
Cytokinetics CEO Robert Blum sold $7.3M in open-market shares (97,926 shares at $69.33 and 7,500 at $73.44) alongside director Robert Landry selling $147K and EVP Fady Malik selling $264K, totaling ~$7.7M in insider sales over a 7-day window. The CEO's sales coincide with derivative exercises and gifts, but the open-market sales are material at ~0.08% of the $9.6B market cap. This cluster follows a pattern of negative T+20 drift on prior neutral reports, and the selling is concentrated in C-suite, which per academic literature is a weak signal for sales but notable at this scale given the company's 89% analyst bullishness and recent institutional accumulation.
Key Financial Metrics
Key Facts
- CEO Robert Blum sold 97,926 shares open-market at $69.33 for $6.79M on 2026-09-15
- CEO Blum also sold 7,500 shares at $73.44 for $551K on 2026-09-14
- EVP R&D Fady Malik sold 3,500 shares at $75.46 for $264K on 2026-09-08
- Director Robert Landry sold 1,000 shares at $72.13 and 1,000 at $74.66, total $147K
- Total open-market insider sales: ~$7.7M, representing ~0.08% of $9.6B market cap
- CEO also exercised 7,500 derivative shares at $10.60 and gifted 99,276 shares at $0
- Prior CYTK reports show 0% win rate at T+20 with avg -6.12% return across 6 settled reports
Financial Impact
Insider sales of ~$7.7M open-market, ~0.08% of market cap; non-cash gifts and exercises add no economic value
Risk Factors
- Insider sales may signal management's view that the stock is fully valued or that a catalyst is approaching
- Prior CYTK reports show persistent negative T+20 drift regardless of sentiment
- CEO's derivative exercise and concurrent sale suggests tax-motivated liquidity rather than pure bearish view
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1789539121524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access